Cocrystal pharma announces favorable safety data from the phase 1 study with oral antiviral cc-42344 for the treatment of pandemic and seasonal influenza a

Bothell, wash., nov. 17, 2022 (globe newswire) -- cocrystal pharma, inc. (nasdaq: cocp) today announced that cc-42344 demonstrated a favorable safety profile in both the single-ascending dose and the multiple-ascending dose portions of the ongoing phase 1 study. cc-42344 is a broad-spectrum oral antiviral for the treatment of pandemic and seasonal influenza a with a novel mechanism of action.
COCP Ratings Summary
COCP Quant Ranking